Jefferies Downgrades PTC Therapeutics to Hold, Lowers Price Target to $76

Jefferies analyst Faisal Khurshid has downgraded PTC Therapeutics (NASDAQ: PTCT) from a Buy rating to Hold. The price target for the stock has also been reduced from $91 to $76.